Unique ID issued by UMIN | UMIN000036853 |
---|---|
Receipt number | R000041983 |
Scientific Title | Examination about the effect of the efficacy and safety by the presence or absence of the combination of romosozumab and active vitamin D3 preparation |
Date of disclosure of the study information | 2019/05/27 |
Last modified on | 2019/05/26 10:41:09 |
Examination about the effect of the efficacy and safety by the presence or absence of the combination of romosozumab and active vitamin D3 preparation
Examination about the effect of the efficacy and safety by the presence or absence of the combination of romosozumab and active vitamin D3 preparation
Examination about the effect of the efficacy and safety by the presence or absence of the combination of romosozumab and active vitamin D3 preparation
Examination about the effect of the efficacy and safety by the presence or absence of the combination of romosozumab and active vitamin D3 preparation
Japan |
osteoporosis
Orthopedics |
Others
NO
The aim of this study is for patients with osteoporosis, combined with romosozumab alone, in combination with 2 active vitamin D3 preparations romosozumab + eldecalcidol, romosozumab + alphacalcidol divided into 3 groups, combined with active vitamin D3 for romosozumab administration Verify the effectiveness and safety of
Safety,Efficacy
Exploratory
Pragmatic
Not applicable
Bone mineral density changes before and 6 months and 12monthsafter start of treatment
Occurrence of hypocalcemia
Other adverse event
Interventional
Parallel
Randomized
Individual
Single blind -participants are blinded
Active
YES
NO
Institution is considered as a block.
YES
Central registration
3
Treatment
Medicine |
romosozumab group
romosozumab + eldecalcidol group
romosozumab + alfacalcidol group
20 | years-old | <= |
Not applicable |
Male and Female
1:Osteoporosis patients who are more than 20 years old
2:Patients who agree with this study
1:Patients who are allergic to romosozumab or eldecalcidol or alfacalcidol
2:Pregnant or breast-feeding patients
3:Hypocalcemia
4:Patients with severe renal function (eGFR 30 ml / min / 1.73 m2) or patients undergoing dialysis
5:Patients at risk of hypercalcemia (patients with renal dysfunction, patients with malignancy, patients with primary hyperparathyroidism)
6:Patients with severe liver dysfunction
7:Patients with urolithiasis and patients with a history of their history
8:Others, patients judged by the research director as inappropriate
90
1st name | Yukio |
Middle name | |
Last name | Nakamura |
Shinshu University School of Medicine
Dept. of Orthopaedic Surgery
390-8621
Asahi 3-1-1, Matsumoto 3908621, Japan
0263372659
yxn14@aol.jp
1st name | Yukio |
Middle name | |
Last name | Nakamura |
Shinshu University School of Medicine
Dept. of Orthopaedic Surgery
390-8621
Asahi 3-1-1, Matsumoto 3908621, Japan
0263372659
yxn14@aol.jp
Shinshu University School of Medicine
Dept. of Orthopaedic Surgery
Shinshu University School of Medicine
Dept. of Orthopaedic Surgery
Self funding
Shinshu University School of Medicine Dept. of Orthopaedic Surgery
Asahi 3-1-1, Matsumoto 3908621, Japan
0263372659
yxn14@aol.jp
NO
2019 | Year | 05 | Month | 27 | Day |
Partially published
Preinitiation
2019 | Year | 05 | Month | 13 | Day |
2019 | Year | 05 | Month | 23 | Day |
2019 | Year | 05 | Month | 26 | Day |
2024 | Year | 05 | Month | 13 | Day |
2019 | Year | 05 | Month | 26 | Day |
2019 | Year | 05 | Month | 26 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000041983